학술논문
Neutralization activity of HCWs' sera after Omicron XBB.1.5-adapted monovalent COVID-19 mRNA vaccination.
Document Type
Editorial & Opinion
Author
Amano M; Department of Clinical Retrovirology, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan. Electronic address: mamano@kumamoto-u.ac.jp.; Ichikawa Y; Kumamoto General Hospital, Japan Community Healthcare Organization, Kumamoto, Japan.; Matsumoto S; Kumamoto General Hospital, Japan Community Healthcare Organization, Kumamoto, Japan.; Higashi-Kuwata N; Department of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.; Takamatsu Y; Department of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.; Matsushita S; Department of Clinical Retrovirology, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.; Shimada S; Kumamoto General Hospital, Japan Community Healthcare Organization, Kumamoto, Japan.; Mitsuya H; Department of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.
Source
Publisher: W.B. Saunders Country of Publication: England NLM ID: 7908424 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-2742 (Electronic) Linking ISSN: 01634453 NLM ISO Abbreviation: J Infect Subsets: MEDLINE
Subject
Language
English
Abstract
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.